Evaxion Biotech Completes Successful Public Offering
Evaxion Biotech A/S (NASDAQ: EVAX), a company at the forefront of AI-Immunology™, recently closed a significant public offering, raising a total of $10.8 million. This funding is crucial as it supports the company’s mission to innovate in vaccine development through artificial intelligence-driven methodologies.
Details of the Offering
In this public offering, Evaxion announced that it successfully sold 3,997,361 American Depositary Shares (ADSs) and accompanying warrants to purchase up to 50% of the offered ADSs, with a public price set at $2.71 per ADS. For every two ADSs purchased, investors received one warrant. This strategic offering reflects investor confidence in Evaxion's potential to transform the biotech landscape.
Participation from Key Investors
The offering attracted notable investors, including MSD Global Health Innovation Fund, the corporate venture capital arm of Merck & Co., Inc. This collaboration highlights the increasing interest from established healthcare sectors in Evaxion’s pioneering approach to immunotherapy. Additionally, members of Evaxion’s Board of Directors and Management also participated, demonstrating their commitment to the company’s growth.
Warrants and Share Structure
Each warrant associated with the ADSs carries an exercise price of $2.71, becoming exercisable immediately upon issuance and expiring five years later. It’s important to note that each ADS is equivalent to fifty ordinary shares of Evaxion, which positions the offering as a significant move to bolster its equity base.
Use of Proceeds
The financial resources garnered through this offering are earmarked for several strategic initiatives. Specifically, Evaxion plans to advance its preclinical and clinical pipeline, focusing on groundbreaking AI-backed vaccines designed to tackle various health challenges. The funding will also support ongoing operating expenses and essential working capital, ensuring the company retains its operational agility.
Engagement with Regulatory Bodies
The offering was conducted in compliance with regulatory requirements, as outlined in a registration statement declared effective by the Securities and Exchange Commission (SEC). This step showcases Evaxion's dedication to maintaining transparency and adhering to industry standards.
About Evaxion Biotech
Evaxion Biotech is uniquely positioned in the TechBio arena, harnessing AI technology to revolutionize vaccine development. Their AI-Immunology™ platform develops predictive models that decode the complexities of the human immune system, paving the way for novel immunotherapies against cancer, viral infections, and bacterial diseases. This innovative approach not only underscores the company's commitment to healthcare innovation but also exemplifies its potential for significant impact on patient lives.
Commitment to Innovation
With a clear focus on addressing unmet medical needs, Evaxion's research spans both personalized oncology vaccines and infectious disease therapeutics. This dual pipeline illustrates the company’s strategic vision of transforming healthcare by offering tailored treatment options that are grounded in cutting-edge research and development.
Contact Information for Inquiries
For further questions or detailed information regarding this public offering or the company's innovative pipeline, potential investors and interested parties are encouraged to reach out to:
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
Email: mak@evaxion.ai
Frequently Asked Questions
What was the total amount raised by Evaxion in the public offering?
Evaxion successfully raised a total of $10.8 million from the public offering.
Who participated in the offering?
Key participants included MSD Global Health Innovation Fund and several healthcare investment funds, alongside Evaxion’s Board and Management.
What are the terms of the warrants issued in the offering?
The warrants have an exercise price of $2.71 per ADS and are valid for five years from the issuance date.
How will the funds be used by Evaxion?
The funds raised will be used to advance the company's clinical pipeline, continue operational expenses, and boost working capital.
What technology underpins Evaxion's vaccine development?
Evaxion utilizes its proprietary AI-Immunology™ platform, which employs artificial intelligence to develop innovative immunotherapies.
